Semaglutide Tied to Lower Psychiatric Hospitalization in Bipolar Disorder
A Swedish study of nearly 15,000 people with bipolar disorder found that those taking semaglutide had a 21% lower risk of psychiatric hospitalization compared to periods without the drug. The effect was specific to semaglutide, not other GLP-1 medications, suggesting possible anti-inflammatory or brain-related mechanisms.
The research analyzed Swedish national health records spanning 15 years, tracking nearly 15,000 individuals diagnosed with bipolar disorder who had been prescribed GLP-1 drugs. Notably, the protective association was exclusive to semaglutide; other similar medications like liraglutide and dulaglutide showed no such link to reduced psychiatric admissions.
The study's authors propose that semaglutide's impact on brain signaling might lower inflammation and cellular stress, potentially aiding mood stability. Since diabetes, obesity, and bipolar disorder often overlap, these findings highlight a shared biological basis. The team emphasizes that a randomized controlled trial is necessary to confirm whether semaglutide directly improves psychiatric outcomes.
This observational finding could reshape psychiatric care for the millions living with bipolar disorder, particularly those who also struggle with metabolic conditions. If future trials confirm a causal link, semaglutide may become a dual-purpose therapy, potentially reducing hospitalizations and easing the burden on healthcare systems. However, the lack of effect from other GLP-1 drugs suggests a unique mechanism, so clinicians should remain cautious about prescribing it solely for mood stabilization until stronger evidence emerges.